Fingerprint
Dive into the research topics of 'Ocrelizumab not recommended in France for patients with primary progressive multiple sclerosis while recommended in England: a review comparing the assessment by HAS and NICE'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically